EHS
EHS

FDA approves Cassipa for medication-assisted treatment for opioid dependence

Today, the FDA announced the approval of Cassipa, developed by Teva Pharmaceuticals for the maintenance treatment of opioid dependence.
“There’s an urgent need to ensure access to, and wider use and understanding of, medication-assisted treatment for opioid use disorder,” Scott Gottlieb, MD, FDA Commissioner, said in the announcement. “The introduction of new treatment options has the potential to broaden access for patients.”
A sublingual film designed to be applied under the tongue, Cassipa (buprenorphine and naloxone, Teva Pharmaceuticals) contains 16 mg of

Source link

EHS
Back to top button